PTU - Polskie Towarzystwo Urologiczne
list of articles:

PSA AND PAP CONCENTRATION IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA BEFORE AND YEAR AFTER ADENOMECTOMY
Article published in Urologia Polska 1995/48/1.

authors

Jan Kulpa, Andrzej Bugajski 1, Ewa Wójcik, Katarzyna Miodońska 1, Urszula Rychlik
Z Zakładu Analityki i Biochemii Klinicznej Centrum Onkologii Instytutu im. M. Sklodowskiej-Curie, Oddział w Krakowie
Kierownik Zakładu: Dr n. chem. J. Kulpa
Dyrektor Centrum Onkologii, Oddział w Krakowie: Prof. dr hab. J. Skołyszewski
1 Z Kliniki Urologii Collegium Medicum Uniwersytetu Jagiellońskiego w Krakowie
Kierownik Kliniki Urologii: Doc. dr hab. A. Bugajski

summary

PSA and PAP concentration were determined in 63 patients with benign prostatic
hyperplasia before and 12 months after adenomectomy. Prior to surgery, increased PSA
concentration was found in 87,3% and increased PAP in 11,1% of patients. Twelve months
after surgery the PSA concentration was significantly lower, compared to the preoperative value
p<0,0001
drop after surgery was considerably smaller, only 2 patients after adenomectomy showed the
marker concentration sligthly exceeding the cut-off value.
Significant correlation was found between the preoperative concentration of both markers
and the enucleated adenoma weight.

references

  1. 1. Althoff E.P., Proppe K.H., Chapman C.M., Lee CH., Prot G.R.: Evaluation of prostate
  2. acid phosphatase and prostate specific antigen in identification of prostate cancer. J. Urol., 1983,
  3. 129, 315. ? 2. Armbruster D.A.: Prostate-specific antigen: Biochemistry, analytical methods,
  4. and clinical application, Clin. Chem., 1993, 39, 181. ? 3. Armitage T.G., Cooper E.H., Newling
  5. D.W.W., Robinson M.R.G., Appleyard /.: The value of the measurement of serum prostate
  6. specific antigen in patients with benign prostatic hyperplasia and untreated prostate cancer. Br.
  7. J. Urol., 1988, 62, 584. ? 4. Becker D.H.: Elevated serum prostate specific antigen (PSA) in
  8. benign prostatic hyperplasia: A retrospective study on 45 patients. W R. Klapdor (ed.) Tumor
  9. Associated Antigens, Oncogenes, Receptors, Cytokines in Tumor Diagnosis and Therapy at the
  10. Beginning of the Nineties. 1992, W. Zuckschwerdt Verlag, Munchen, Bern Wien, New York,
  11. str. 153. ? 5. Bilhartz D.L., Tindali D.J., Oesterling J.E.: Prostate-specific antigen and prostatic
  12. acid phosphatase: Biomolecular and Physiologic characteristics. Urology, 1991, 38, 95. ?
  13. 6. Brawer M.K., Lange H.P.: Prostate-specific antigen: Its role in early detection, staging, and
  14. monitoring of prostate carcinoma. J. Endourology, 1989, 3, 227. ? 7. elernents R., Penney
  15. M.D., Etherington R.J., Griffiths G.J., Hughes H., Peeling W.B.: Volume of normal prostatre, of
  16. prostate cancer, and of benign prostatic hyperplasia: Are correlations with prostate specific
  17. antigen Clinically useful? Prostate, 1992, 4 Suppl., 51. ? 8. Collins G.N., Lee R.J., McKelme
  18. G.B., Rogers A.C.N., Hehir H.: Relationship between prostate specific antigen, prostate volume
  19. and age in the benign prostate. Br. J. Urol., 1993, 71, 445. ? 9. Kulpa J., Bugajski A., Wójcik
  20. E., Jaszczyński J.\ Objętość gruczołu a stężenie PAP i PSA u chorych na gruczolak stercza.
  21. Urol. Pol., 1994, 47, 99. ? 10. Kulpa J., Leńko J., Kwinta A., Wójcik E., Marczyńska A.:
  22. Kształtowanie się stężenia kwaśnej fosfatazy sterczowej w osoczu krwi u chorych operowanych
  23. z powodu gruczolaka stercza. Urol. Pol., 1986, 39, 93.
  24. 11. Oesterling J.E.: Prostate specific antigen: A critical assessment of the most useful tumor
  25. marker for adenocarcinoma of the prostate. J. Urol., 1991. 145,907. ? 12. Oesterling J.E., Chan
  26. D.W., Epstein J.I., Kimball A.M., Bruzek D.J., Rock R.C., Brendler Ch.B.: Prostate specific
  27. antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated
  28. with radical prostatectomy. J. Urol., 1988, 139, 766. ? 13. Partin A.W., Carter H.B., Chan
  29. W.D., Epstein JJ., Oesterling J.E., Rock R.C., Weber J.P., Walsh P.C: Prostate specific antigen
  30. in the staging of localized prostate cancer: Influence of tumor differentiation, tumor volume and
  31. benign hyperplasia. J. Urol., 1990. 143, 747. ? 14. Rainwater L.M., Morgan W.R., Klee G.G.,
  32. Zincke H.\ Prostate-specific antigen testing in untreated and treated prostatic adenocarcinoma.
  33. Mayo Clin. Proc, 1990, 65, 1118. ? 15. Ruckle H.C., Klee G.G., Oesterling J.E.: Prostate-
  34. -specific antigen: Critical issues for the practicing physician. Mayo Clin. Proc, 1994, 69, 59.
  35. ? 16. Sershon P.D., Barry M.J., Oesterling J.E.: Serum Prostate-specific antigen discriminates
  36. weakly between men with benign prostatic hyperplasia and patients with organ-confined
  37. prostate cancer. Eur. Urol., 1994, 25, 282. ? 17. Stamey T.A., Yang N., Hay A.R., McNeal
  38. J.E., Frehia F.S., Redwine E.: Prostate-specific antigen as a serum marker for adenocarcinoma
  39. of the prostate. N. Engl. J. Med., 1987, 317, 909. ? 18. Wang M.C, Valenzuela L.A., Murphy
  40. G.P., Chu T.M.: Purification of human prostate specific antigen. Invest. Urol., 1979,17, 159. ?
  41. 19. Wolf J.M., Scholz A., Boeckmann W., Jakse G.: Differentiation of benign prostatic
  42. hyperplasia and prostate cancer empoying Prostatic-specific antigen density. Eur. Urol., 1994,
  43. 25, 295.